Alnylam Pharmaceuticals demonstrated robust commercial momentum with its RNA interference drug Amvuttra, used in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM). The drug's first full quarter yielded $492 million in sales, doubling year-over-year and surpassing market expectations. Broad formulary adoption and balanced utilization across patient subgroups contributed to the rapid uptake. The success lifted Alnylam's market capitalization beyond the $50 billion threshold, underscoring its growing leadership in RNA-based therapeutics.